FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3–5.

Nephrology

Volumn 21, Issue 7, 2016, Pages 566-573

  Alderson, Helen V ^a,b   Ritchie, James P ^a,b   Middleton, Rachel ^a,b   Larsson, Anders ^c   Larsson, Tobias E ^d   Kalra, Philip A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

biomarkers; CKD MBD; outcomes; prediction; risk

Indexed keywords

BIOLOGICAL MARKER; FETUIN A; FIBROBLAST GROWTH FACTOR 23; OSTEOPROTEGERIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 84976585971     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12664     Document Type: Article

References (33)

1. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare Population, 1998 to 1999. J. Am. Soc. Nephrol. 2005; 16: 489–95.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296–305.
3. Tangri N, Stevens LA, Griffith J et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305: 1553–9.
4. Levin A, Rigatto C, Barrett B et al. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol. Dial. Transplant. 2014; 29: 1037–1047.
5. Peeters MJ, van Zuilen AD, van den Brand JAJG et al. Validation of the kidney failure risk equation in European CKD patients. Nephrol. Dial. Transplant. 2013; 28: 1773–9.
6. Nitta K. Vascular calcification in patients with chronic kidney disease. Ther. Apher. Dial. 2011; 15: 513–21.
7. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005; 68: 1413–8.
8. Garcia-Canton C, Bosch E, Ramirez A et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol. Dial. Transplant. 2011; 26: 2250–6.
9. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–47.
10. Stevens PE, O'donoghue DJ, De Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007; 72: 92–9.
11. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 2004; 95: 1046–57.
12. Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005; 67: 2295–304.
13. Mesquita M, Demulder A, Damry N et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin. Chem. Lab. Med. 2009; 47: 339–46.
14. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol. Dial. Transplant. 2009; 24: 3157–62.
15. Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol. Dial. Transplant. 2010; 25: 1853–8.
16. Hermans MMH, Brandenburg V, Ketteler M et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007; 72: 202–7.
17. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 2011; 22: 1913–22.
18. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin. J. Am. Soc. Nephrol. 2011; 6: 2871–8.
19. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant. 2010; 25: 3983–9.
20. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600–8.
21. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432–9.
22. Hoefield RA, Kalra PA, Lane B, O'donoghue DJ, Foley RN, Middleton RJ. Associations of baseline characteristics with evolution of eGFR in a referred chronic kidney disease cohort. QJM 2013; 106: 915–24.
23. Ritchie J, Rainone F, Green D et al. Extreme elevations in blood pressure and all-cause mortality in a referred CKD population: results from the CRISIS study. Int. J. Hypertens. 2013; 2013: 597906.
24. Levey AS, Bosch JP, Lewis JB, Greene T. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999; 130: 419.
25. Kundu S, Aulchenko YS, van Duijn CM, Janssens ACJW. PredictABEL: an R package for the assessment of risk prediction models. Eur. J. Epidemiol. 2011; 26: 261–4.
26. Lewis JR, Lim WH, Zhu K et al. Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study. Am. J. Nephrol. 2014; 1: 66–74.
27. Svensson M, Dahle DO, Mjoen G et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol. Dial. Transplant. 2012; 27: 2571–5.
28. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100–7.
29. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Eng. J. Med. 2008; 359: 584–92.
30. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 2792–6.
31. Scialla JJ, Xie H, Rahman M et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 2014; 25: 349–60.
32. Seiler S, Rogacev KS, Roth HJ et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4. Clin. J. Am. Soc. Nephrol. 2014; 9: 1049–58.
33. Ärnlöv J, Carlsson AC, Sundström J et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin. J. Am. Soc. Nephrol. 2013; 8: 781–6.